临床误诊误治2025，Vol.38Issue(17)：94-98,5.DOI:10.3969/j.issn.1002-3429.2025.17.020
芪黄益肾汤联合非布司他治疗慢性肾脏病3～5期(脾肾亏虚证)合并高尿酸血症的效果观察
Observation on the effect of Qihuang Yishen decoction combined with febustat in the treatment of stage 3-5 chronic kidney disease with spleen and kidney deficiency syndrome complicated with hyperuricemia
摘要
Abstract
Objective To explore the effect of Qihuang Yishen decoction combined with Febustat in the treatment of patients with stage 3-5 chronic kidney disease(CKD)with spleen and kidney deficiency syndrome complicated with hyperuricemia.Methods A total of 96 patients with stage 3-5 CKD with spleen and kidney deficiency syndrome complicated with hyperuricemia who were admitted from January 2021 to December 2023 were selected and divided into a Western medicine treatment group(conventional treatment+Febustine treatment,n=48)and a combination group(treated with Qihuang Yishen decoction on the basis of the Western medicine treatment group,n=48)by random number table method.Both groups received continuous treatment for 2 months.The therapeutic effects of CKD and the target achievement rate of blood uric acid in the two groups were compared.Changes in the traditional Chinese medicine(TCM)syndrome score,serum lipoprotein-associated phospholipase A2(Lp-PLA2),vascular endothelial growth factor(VEGF),renal function indicators before and after treatment,as well as the occurrence of adverse reactions were also compared.Results The total effective rate of CKD treatment and the target achievement rate of blood uric acid in the combination group were both higher than those in the Western medicine treatment group(P<0.05).After treatment,the scores of the primary and secondary symptoms of TCM syndromes in both groups decreased,which were lower in the combination group than in the Western medicine treatment group(P<0.05,P<0.01).After treatment,the levels of Lp-PLA2 and VEGF in both groups decreased,which were lower in the combination group than in the Western medicine treatment group(P<0.05,P<0.01).After treatment,both blood urea nitrogen(BUN)and serum creatinine(Scr)decreased in both groups,while glomerular filtration rate(eGFR)increased.Moreover,BUN and Scr in the combination group were lower than those in the Western medicine treatment group,and eGFR was higher than that in the Western medicine treatment group(P<0.05,P<0.01).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Qihuang Yishen decoction combined with Febustat can significantly increase the target achievement rate of blood uric acid in patients with stage 3-5 CKD with spleen and kidney deficiency syndrome complicated with hyperuricemia,reduce the levels of Lp-PLA2 and VEGF,improve the clinical symptoms and renal function of patients,and has good safety.关键词
芪黄益肾汤/非布司他/慢性肾脏病/高尿酸血症/中医证候/脂蛋白相关磷脂酶A2/血肌酐/药物毒性Key words
Qihuang Yishen decoction/Febustat/chronic kidney disease/hyperuricemia/TCM syndromes/lipoprotein-associated phospholipase A2/blood creatinine/drug toxicity引用本文复制引用
潘军,宣建宗,吴亮亮,刘源,王义元,张海银,董建睿..芪黄益肾汤联合非布司他治疗慢性肾脏病3～5期(脾肾亏虚证)合并高尿酸血症的效果观察[J].临床误诊误治,2025,38(17):94-98,5.基金项目
安徽省中医药高水平传承人才支持项目[皖中医药发展秘(2024)1号] （2024）
2022年度安徽省中医药传承创新科研项目(2022CCYB12) （2022CCYB12）
2024年度安徽省中医药传承创新科研项目(2024CCCX056) （2024CCCX056）
2024年度滁州市临床重点专科建设项目[滁卫健函(2024)47号] （2024）
